CN101998861A - 用gnrh拮抗剂地加瑞克治疗前列腺癌的方法 - Google Patents

用gnrh拮抗剂地加瑞克治疗前列腺癌的方法 Download PDF

Info

Publication number
CN101998861A
CN101998861A CN2009801127793A CN200980112779A CN101998861A CN 101998861 A CN101998861 A CN 101998861A CN 2009801127793 A CN2009801127793 A CN 2009801127793A CN 200980112779 A CN200980112779 A CN 200980112779A CN 101998861 A CN101998861 A CN 101998861A
Authority
CN
China
Prior art keywords
treatment
compositions
experimenter
degarelix
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801127793A
Other languages
English (en)
Chinese (zh)
Inventor
蒂内·科尔·奥尔森
波-埃里克·佩尔森
佩尔·坎托
艾格伯特·A·范德默朗
延斯-克里斯蒂安·斯洛特·延森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huiling International Pharmaceutical Switzerland Co ltd
Original Assignee
Huiling International Pharmaceutical Switzerland Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101998861(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Huiling International Pharmaceutical Switzerland Co ltd filed Critical Huiling International Pharmaceutical Switzerland Co ltd
Priority to CN201710169651.7A priority Critical patent/CN107412726A/zh
Publication of CN101998861A publication Critical patent/CN101998861A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2009801127793A 2008-02-11 2009-02-10 用gnrh拮抗剂地加瑞克治疗前列腺癌的方法 Pending CN101998861A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710169651.7A CN107412726A (zh) 2008-02-11 2009-02-10 用gnrh拮抗剂地加瑞克治疗前列腺癌的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
US61/027,741 2008-02-11
EP08250703.9 2008-02-29
EP08250703 2008-02-29
PCT/IB2009/000350 WO2009101530A1 (en) 2008-02-11 2009-02-10 Method of treating prostate cancer with the gnrh antagonist degarelix

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201710169651.7A Division CN107412726A (zh) 2008-02-11 2009-02-10 用gnrh拮抗剂地加瑞克治疗前列腺癌的方法
CN201410247166.3A Division CN103990107A (zh) 2008-02-11 2009-02-10 用gnrh拮抗剂地加瑞克治疗前列腺癌的方法

Publications (1)

Publication Number Publication Date
CN101998861A true CN101998861A (zh) 2011-03-30

Family

ID=39718285

Family Applications (4)

Application Number Title Priority Date Filing Date
CN2009801127793A Pending CN101998861A (zh) 2008-02-11 2009-02-10 用gnrh拮抗剂地加瑞克治疗前列腺癌的方法
CN200980104713XA Ceased CN101939020B (zh) 2008-02-11 2009-02-10 地加瑞克在制备治疗转移期前列腺癌的药物中的应用
CN201710169651.7A Pending CN107412726A (zh) 2008-02-11 2009-02-10 用gnrh拮抗剂地加瑞克治疗前列腺癌的方法
CN201410247166.3A Pending CN103990107A (zh) 2008-02-11 2009-02-10 用gnrh拮抗剂地加瑞克治疗前列腺癌的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN200980104713XA Ceased CN101939020B (zh) 2008-02-11 2009-02-10 地加瑞克在制备治疗转移期前列腺癌的药物中的应用
CN201710169651.7A Pending CN107412726A (zh) 2008-02-11 2009-02-10 用gnrh拮抗剂地加瑞克治疗前列腺癌的方法
CN201410247166.3A Pending CN103990107A (zh) 2008-02-11 2009-02-10 用gnrh拮抗剂地加瑞克治疗前列腺癌的方法

Country Status (25)

Country Link
US (17) US20090203623A1 (https=)
EP (7) EP2650012B1 (https=)
JP (12) JP5924866B2 (https=)
KR (8) KR20220009504A (https=)
CN (4) CN101998861A (https=)
AU (2) AU2009213751B2 (https=)
BR (2) BRPI0908127A2 (https=)
CA (3) CA2714445C (https=)
CY (3) CY1115561T1 (https=)
DK (3) DK2505204T3 (https=)
EA (4) EA017582B1 (https=)
ES (3) ES2532709T3 (https=)
HK (1) HK1198243A1 (https=)
HR (3) HRP20140665T1 (https=)
IL (3) IL207295A (https=)
JO (1) JOP20090061B1 (https=)
MX (2) MX2010008817A (https=)
NZ (4) NZ587057A (https=)
PL (3) PL2505204T3 (https=)
PT (3) PT2650012E (https=)
RU (2) RU2504393C2 (https=)
SI (3) SI2249859T1 (https=)
TW (2) TWI539959B (https=)
WO (2) WO2009101533A1 (https=)
ZA (1) ZA201005697B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102204889A (zh) * 2011-05-23 2011-10-05 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
TWI539959B (zh) * 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
MX2011011431A (es) * 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
LT2632934T (lt) 2010-10-27 2017-01-10 Ferring B.V. Degarelikso ir jo tarpinių darinių gamybos būdas
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
AU2012225232B2 (en) 2011-03-09 2016-05-12 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
JP6518585B2 (ja) 2012-05-14 2019-05-22 リチャード ジー． ペステル がんの治療のためのｃｃｒ５の修飾薬の使用
PL4512390T1 (pl) 2012-06-01 2025-09-01 Ferring B.V. Wytwarzanie degareliksu
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
WO2014186608A1 (en) * 2013-05-15 2014-11-20 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
US10821152B2 (en) 2014-08-26 2020-11-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
AU2016261770B2 (en) * 2015-05-12 2022-06-02 Drexel University Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
BR112019014192A2 (pt) * 2017-01-30 2020-02-11 Antev Limited Composição compreendendo pelo menos um antagonista de gnrh
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
AU2018419533A1 (en) 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
EP3829584A4 (en) * 2018-08-01 2022-06-08 Abbvie Inc. DOSAGE SCHEDULES FOR ELAGOLIX
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494B (zh) * 2023-03-02 2024-07-09 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ZA735680B (en) * 1972-09-21 1974-07-31 Hoffmann La Roche Polypeptides
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
DE2862341D1 (en) 1977-12-26 1983-11-24 Ihara Chemical Ind Co Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE69214818T2 (de) 1991-04-25 1997-02-27 Romano S.-Cergue Deghenghi LHRH-Antagonisten
EP0556034B2 (en) 1992-02-12 2004-07-21 Daikyo Gomu Seiko Ltd. A medical instrument
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
JP3688381B2 (ja) 1995-03-10 2005-08-24 株式会社東芝 光ディスク原盤露光装置
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5977302A (en) 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
CN1243543C (zh) 1998-07-20 2006-03-01 派普泰克有限公司 生物植入物配方
CN100500692C (zh) * 2000-03-14 2009-06-17 赞塔里斯有限公司 新型lhrh拮抗剂,其制备方法和药物用途
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
BRPI0314546B8 (pt) 2002-09-27 2021-05-25 Zentaris Gmbh composição de gel farmacêutico compreendendo peptídeos farmaceuticamente atvos com liberação sustentada, método para a produção dos mesmos kit.
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
CA2711984A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
ES2589322T3 (es) 2008-02-11 2016-11-11 Safety Syringes, Inc. Jeringa con protector de seguridad de aguja y clip para evitar la liberación del protector durante un proceso de reconstitución
WO2010121835A1 (en) 2009-04-24 2010-10-28 Polypeptide Laboratories A/S Method for the manufacture of degarelix
MX2011011431A (es) 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
IT1399892B1 (it) 2010-03-15 2013-05-09 Spi Tecno Srl Sistema per l illuminazione pubblica
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
LT2632934T (lt) 2010-10-27 2017-01-10 Ferring B.V. Degarelikso ir jo tarpinių darinių gamybos būdas
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
KR20140063602A (ko) 2011-07-15 2014-05-27 훼링 비.브이. 피코설페이트 조성물을 투여하여 대장내시경의 시술 시기를 조절하는 방법
PL4512390T1 (pl) 2012-06-01 2025-09-01 Ferring B.V. Wytwarzanie degareliksu

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN DOEHN,ET AL.: "Drug evaluation: Degarelix-a potential new therapy for prostate cancer", 《IDRUGS》 *
GITTELMAN M,ET AL: "A multicentre, randomised one year dose-finding study of degarelix, a gonadotrophin-releasing hormone (GnRH) receptor blocker, in prostate cancer patients", 《UROLOGY》 *
TAMMELA T.ET AL.: "Degarelix-a phase 11 multicentre randomized dose-escalating study testing a novel gnrh receptor blocker in prostate cancer patients", 《EUROPEAN UROLOGY SUPPLEMENTS》 *
VAN POPPEL H, ET AL: "LONG-TERM EVALUATION OF DEGARELIX, A GONADOTROPHIN-RELEASING HORMONE(GNRH) RECEPTOR BLOCKER, INVESTIGATED IN A MULTICENTRE RANDOMISED STUDY IN PROSTATE CANCER (CAP) PATIENTS", 《EUROPEAN UROLOGY SUPPLEMENTS 》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102204889A (zh) * 2011-05-23 2011-10-05 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法

Also Published As

Publication number Publication date
EP2249859B1 (en) 2014-04-23
ZA201005697B (en) 2014-01-24
TWI442932B (zh) 2014-07-01
US20210128673A1 (en) 2021-05-06
EP4257197A2 (en) 2023-10-11
HK1190912A1 (en) 2014-07-18
HRP20150633T1 (hr) 2015-07-31
TW200938217A (en) 2009-09-16
US9877999B2 (en) 2018-01-30
CN107412726A (zh) 2017-12-01
US20140349935A1 (en) 2014-11-27
PL2650012T3 (pl) 2015-08-31
US8841081B2 (en) 2014-09-23
KR20150091543A (ko) 2015-08-11
CA2714444A1 (en) 2009-08-20
MX2010008817A (es) 2010-09-09
JP2025160167A (ja) 2025-10-22
JP2016193910A (ja) 2016-11-17
NZ603932A (en) 2014-04-30
US20240316142A1 (en) 2024-09-26
AU2009213751A1 (en) 2009-08-20
DK2505204T3 (da) 2015-03-16
JP7400029B2 (ja) 2023-12-18
US20220323538A1 (en) 2022-10-13
SI2650012T1 (sl) 2015-06-30
EP2249859A1 (en) 2010-11-17
CY1115561T1 (el) 2017-01-04
PL2505204T3 (pl) 2015-05-29
US20130029910A1 (en) 2013-01-31
TW200938218A (en) 2009-09-16
KR20250028541A (ko) 2025-02-28
KR20100123714A (ko) 2010-11-24
KR101542480B1 (ko) 2015-08-07
ES2540235T3 (es) 2015-07-09
JP5924866B2 (ja) 2016-05-25
US20090203623A1 (en) 2009-08-13
JP2022133426A (ja) 2022-09-13
EA201300742A1 (ru) 2014-02-28
EP2650012A1 (en) 2013-10-16
WO2009101530A1 (en) 2009-08-20
MX2010008816A (es) 2010-09-07
EA201300741A1 (ru) 2014-02-28
US20220031801A1 (en) 2022-02-03
NZ587088A (en) 2012-12-21
JP2018039814A (ja) 2018-03-15
RU2504394C2 (ru) 2014-01-20
DK2249859T3 (da) 2014-06-02
HK1176552A1 (en) 2013-08-02
EA200901075A1 (ru) 2010-04-30
JP2022184898A (ja) 2022-12-13
EP2505204B1 (en) 2014-12-24
CY1116289T1 (el) 2017-02-08
US20170290879A1 (en) 2017-10-12
KR20100126362A (ko) 2010-12-01
US20200237854A1 (en) 2020-07-30
IL223124A0 (en) 2012-12-31
EP3360565A1 (en) 2018-08-15
JP6189234B2 (ja) 2017-08-30
US20170035833A1 (en) 2017-02-09
KR20220009504A (ko) 2022-01-24
KR20140130757A (ko) 2014-11-11
EA017582B1 (ru) 2013-01-30
KR20180118830A (ko) 2018-10-31
AU2009213748A1 (en) 2009-08-20
EP4257197A3 (en) 2023-11-29
US11826397B2 (en) 2023-11-28
DK2650012T3 (da) 2015-06-15
RU2010133481A (ru) 2012-03-20
US12514898B2 (en) 2026-01-06
IL207400A (en) 2014-12-31
JP2011511785A (ja) 2011-04-14
US20220218782A1 (en) 2022-07-14
RU2010133480A (ru) 2012-03-20
US9415085B2 (en) 2016-08-16
NZ587057A (en) 2012-12-21
AU2009213748B2 (en) 2014-03-13
US20250134948A1 (en) 2025-05-01
WO2009101533A1 (en) 2009-08-20
PL2249859T3 (pl) 2014-10-31
AU2009213748B9 (en) 2014-05-22
US10729739B2 (en) 2020-08-04
EA036695B1 (ru) 2020-12-09
CN101939020A (zh) 2011-01-05
HK1145011A1 (en) 2011-03-25
US20220226422A1 (en) 2022-07-21
JP2024028869A (ja) 2024-03-05
JP6254042B2 (ja) 2017-12-27
JOP20090061B1 (ar) 2021-08-17
JP2016216455A (ja) 2016-12-22
HRP20150290T1 (hr) 2015-04-10
JP2011511786A (ja) 2011-04-14
JP2014167009A (ja) 2014-09-11
HK1198243A1 (en) 2015-03-20
EA200901074A1 (ru) 2010-04-30
PT2249859E (pt) 2014-07-31
JP5876652B2 (ja) 2016-03-02
US12533387B2 (en) 2026-01-27
CA2714445A1 (en) 2009-08-20
KR20230088848A (ko) 2023-06-20
EP2505204A3 (en) 2013-01-09
IL207295A0 (en) 2010-12-30
CN103990107A (zh) 2014-08-20
NZ603958A (en) 2013-03-28
EP2799085A1 (en) 2014-11-05
RU2504393C2 (ru) 2014-01-20
JP6618967B2 (ja) 2019-12-11
US10695398B2 (en) 2020-06-30
BRPI0908129A2 (pt) 2015-08-04
HRP20140665T1 (hr) 2014-10-10
EP2505204A2 (en) 2012-10-03
US10973870B2 (en) 2021-04-13
CA2714445C (en) 2018-01-16
US11766468B2 (en) 2023-09-26
EP2249858A1 (en) 2010-11-17
EA026521B1 (ru) 2017-04-28
IL207295A (en) 2015-03-31
JP2014141505A (ja) 2014-08-07
US9579359B2 (en) 2017-02-28
SI2505204T1 (sl) 2015-04-30
CN101939020B (zh) 2012-12-26
PT2505204E (pt) 2015-03-26
US20140113870A1 (en) 2014-04-24
EP2650012B1 (en) 2015-03-25
ES2532709T3 (es) 2015-03-31
TWI539959B (zh) 2016-07-01
AU2009213751B2 (en) 2014-09-25
JP2026027448A (ja) 2026-02-18
US20220218783A1 (en) 2022-07-14
SI2249859T1 (sl) 2014-08-29
US20090203622A1 (en) 2009-08-13
CY1116341T1 (el) 2017-02-08
CA3235099A1 (en) 2009-08-20
PT2650012E (pt) 2015-06-30
US20190167755A1 (en) 2019-06-06
BRPI0908127A2 (pt) 2015-08-04
IL207400A0 (en) 2010-12-30
ES2479441T3 (es) 2014-07-24
EA020543B1 (ru) 2014-12-30

Similar Documents

Publication Publication Date Title
JP7400029B2 (ja) Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
JP7104003B2 (ja) Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
US20260124269A1 (en) METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
AU2014203174B2 (en) Method of treating prostate cancer with the gnrh antagonist degarelix
HK40099992A (en) Treatment of metastatic stage prostate cancer with degarelix
HK1176552B (en) Method of treating prostate cancer with the gnrh antagonist degarelix

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110330